|
DSGN
|
Design Therapeutics, Inc.
|
0.19%
|
US
|
NASDAQ
|
|
REPL
|
Replimune Group, Inc.
|
0.16%
|
US
|
NASDAQ
|
|
LYEL
|
Lyell Immunopharma, Inc.
|
0.16%
|
US
|
NASDAQ
|
|
ITOS
|
iTeos Therapeutics, Inc.
|
0.16%
|
US
|
NASDAQ
|
|
CRNX
|
Crinetics Pharmaceuticals, Inc.
|
0.16%
|
US
|
NASDAQ
|
|
SANA
|
Sana Biotechnology, Inc.
|
0.15%
|
US
|
NASDAQ
|
|
NRIX
|
Nurix Therapeutics, Inc.
|
0.15%
|
US
|
NASDAQ
|
|
FATE
|
Fate Therapeutics, Inc.
|
0.15%
|
US
|
NASDAQ
|
|
EGRX
|
Eagle Pharmaceuticals, Inc.
|
0.15%
|
US
|
NASDAQ
|
|
ATRA
|
Atara Biotherapeutics, Inc.
|
0.15%
|
US
|
NASDAQ
|
|
MCRB
|
Seres Therapeutics, Inc.
|
0.14%
|
US
|
NASDAQ
|
|
ANAB
|
AnaptysBio, Inc.
|
0.14%
|
US
|
NASDAQ
|
|
ALEC
|
Alector, Inc.
|
0.14%
|
US
|
NASDAQ
|
|
ACET
|
Adicet Bio, Inc.
|
0.13%
|
US
|
NASDAQ
|
|
KNSA
|
Kiniksa Pharmaceuticals, Ltd.
|
0.12%
|
US
|
NASDAQ
|
|
CRBU
|
Caribou Biosciences, Inc.
|
0.12%
|
US
|
NASDAQ
|
|
TSVT
|
2seventy bio, Inc.
|
0.11%
|
US
|
NASDAQ
|
|
NUVL
|
Nuvalent, Inc.
|
0.11%
|
US
|
NASDAQ
|
|
ERAS
|
Erasca, Inc
|
0.10%
|
US
|
NASDAQ
|
|
CCCC
|
C4 Therapeutics, Inc.
|
0.10%
|
US
|
NASDAQ
|